Nuvalent (NUVL) Share-based Compensation (2020 - 2026)
Nuvalent (NUVL) posted Share-based Compensation of $226.2 million for Q1 2026, up 940.77% on a QoQ basis from $21.7 million in Q4 2025, and up 28245.86% year-over-year from N/an in Q1 2025.
Nuvalent (NUVL) Share-based Compensation (2020 - 2026) Analysis & Trends
Nuvalent's Share-based Compensation history runs 7 years deep, the most recent figure standing at $226.2 million for Q1 2026.
- Quarterly Share-based Compensation rose 28245.86% year-over-year to $226.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.2 million (up 1832.14% YoY) and the FY2025 annual result came in at $170.4 million, up 17.92% from the prior year.
- Share-based Compensation was $226.2 million for Q1 2026 at Nuvalent, up from $21.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $226.2 million in Q1 2026 and bottomed at -$44.4 million in Q4 2024.
- A 5-year average of $19.4 million and a median of $6.9 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation slumped 693.34% — and 2026, when it surged 28245.86%.
- Nuvalent's Share-based Compensation stood at $3.0 million in 2022, then jumped by 148.26% to $7.5 million in 2023, then slumped by 693.34% to -$44.4 million in 2024, then jumped by 148.91% to $21.7 million in 2025, then jumped by 940.77% to $226.2 million in 2026.
- Business Quant data shows NUVL's Share-based Compensation at $226.2 million in Q1 2026, $21.7 million in Q4 2025, and $22.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 226.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 226.20 Mn |
| Mar 31, 2026 | 226.20 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Mar 31, 2025 | 798,000.00 |
| Mar 31, 2025 | 798,000.00 |
| Dec 31, 2024 | -44.44 Mn |
| Dec 31, 2024 | -44.44 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Dec 31, 2023 | 7.49 Mn |